OQROGet OQRO Pro
Insider trade

Maxcyte (MXCT)Director sold ~$22K

Rekha Hemrajani, Director at Maxcyte, sold ~$22K of Maxcyte shares.

~$22K
Approx. value · 11K sh @ $2.09
40K
Holds after · shares reported
Traded
Jun 25, 2025
Filed
Aug 27, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Jun 25, 2025 · this disclosureInsiderDirector sold ~$22K of MXCT shares in the open market

What came next

  1. Aug 13, 2025Insider · 5 peopleInsiders: 5 purchases (~$480K)
  2. Sep 22, 2025Company filing · Form 8-K · Restructuring, Reg FDAnnounced job cuts, closures or a restructuring, and shared information with investors“On September 22, 2025, the Board of Directors of MaxCyte, Inc. approved a workforce reduction plan (the “Plan”) as part of the Company’s ongoing efforts to streamline operations, improve its cost structure, and align resources with strategic priorities.”
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Maxcyte

For Maxcyte, OQRO holds 1 federal contract award dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its MXCT page.

Other recent filings by Rekha Hemrajani, Director

The full history of Rekha Hemrajani, Director is on the profile page.

How this filing works

Other disclosures at Maxcyte

Everything OQRO holds on this company is on its MXCT page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO ProAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data